Wire · operational-macro
AstraZeneca targets $1.5B in savings; Ayrmid bids for Karyopharm; Sanofi pays $125M to Novavax
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
AstraZeneca is aiming for $1.5 billion in annual savings by restructuring and refocusing R&D, Ayrmid is bidding for bankrupt US drugmaker Karyopharm to expand its cancer portfolio, and Sanofi has started a Phase 3 trial combining flu and COVID vaccines with milestone payments to Novavax.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech firm needs to weigh new opportunities or risks from AstraZeneca’s cutbacks and Ayrmid’s aggressive acquisition moves in oncology; timing your pitch or partnership could capture orphaned pipeline assets and early-stage funding shifts.
◆ Coverage
1 source · 3 Nov 2026
◆ Related on Wire
◆ Topics